MedTrace Logo

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

NCT00753272 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43695

Last updated 2018-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older. The study design is divided in two surveillance phases: one passive phase along the study during the influenza season and one active surveillance phase during the influenza peak season.

Conditions

Interventions

BIOLOGICAL

GSK Bio's influenza vaccine GSK2186877A

IM administration, two times one annual dose, 3 different lots will be tested

BIOLOGICAL

Fluarix TM

IM administration, two times one annual dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-15
Primary Completion
2010-06-18
Completion
2011-01-05

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • Estonia
  • France
  • Germany
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • Romania
  • Russia
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00753272 on ClinicalTrials.gov